Literature DB >> 35083523

Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.

Tadashi Okamura1, Hiroki Hosoi2, Takeshi Matsufusa1, Yuina Akagi1,3, Ryuta Iwamoto4, Hideki Kosako1, Shogo Murata1, Toshiki Mushino1, Shin-Ichi Murata4, Takashi Sonoki1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35083523     DOI： 10.1007/s00277-021-04744-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  10 in total

1.  Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Authors:  Christopher P Fox; Elizabeth H Phillips; Jeffery Smith; Kim Linton; Eve Gallop-Evans; Claire Hemmaway; Dorothee P Auer; Charlotte Fuller; Andrew J Davies; Pamela McKay; Kate Cwynarski
Journal:  Br J Haematol       Date:  2018-11-23       Impact factor: 6.998

Review 2.  Primary CNS Lymphoma in the Elderly: The Challenge.

Authors:  Tali Siegal; Osnat Bairey
Journal:  Acta Haematol       Date:  2019-02-15       Impact factor: 2.195

Review 3.  The possible role of maintenance treatment for primary central nervous system lymphoma.

Authors:  Osnat Bairey; Tali Siegal
Journal:  Blood Rev       Date:  2018-03-11       Impact factor: 8.250

4.  Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  K Hoang-Xuan; L Taillandier; O Chinot; P Soubeyran; U Bogdhan; J Hildebrand; M Frenay; N De Beule; J Y Delattre; B Baron
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

5.  Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.

Authors:  Xiang-Gui Yuan; Yu-Rong Huang; Teng Yu; Yang Xu; Yun Liang; Xiao-Hong Zhang; Chong-Ran Sun; Xiao-Ying Zhao
Journal:  Ann Hematol       Date:  2019-11-22       Impact factor: 3.673

6.  A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Authors:  Harriet S Walter; Simon A Rule; Martin J S Dyer; Lionel Karlin; Ceri Jones; Bruno Cazin; Philippe Quittet; Nimish Shah; Claire V Hutchinson; Hideyuki Honda; Kevin Duffy; Joseph Birkett; Virginia Jamieson; Nigel Courtenay-Luck; Toshio Yoshizawa; John Sharpe; Tomoya Ohno; Shinichiro Abe; Akihisa Nishimura; Guillaume Cartron; Franck Morschhauser; Christopher Fegan; Gilles Salles
Journal:  Blood       Date:  2015-11-05       Impact factor: 22.113

Review 7.  Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom?

Authors:  Osnat Bairey; Liat Shargian-Alon; Tali Siegal
Journal:  Acta Haematol       Date:  2020-11-26       Impact factor: 2.195

8.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528

9.  Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.

Authors:  Yoshitaka Narita; Motoo Nagane; Kazuhiko Mishima; Yasuhito Terui; Yoshiki Arakawa; Hajime Yonezawa; Katsunori Asai; Noriko Fukuhara; Kazuhiko Sugiyama; Naoki Shinojima; Junsaku Kitagawa; Arata Aoi; Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2021-01-30       Impact factor: 12.300

10.  How we treat primary central nervous system lymphoma.

Authors:  T Calimeri; S Steffanoni; F Gagliardi; A Chiara; A J M Ferreri
Journal:  ESMO Open       Date:  2021-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.